Palbociclib
Refractory Rhabdomyosarcoma
PfizerSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Refractory Rhabdomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- National Cancer Institute (NCI) | Phase 2 | CCC |
ag-120 National Cancer Institute (NCI) | Phase 2 | CCC |
Ensartinib National Cancer Institute (NCI) | Phase 2 | CCC |
Same molecule, other indications
Palbociclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →